Drug Trial News

RSS

Study reveals underrepresentation of older people in COVID-19 trials

A study published today in the Journal of the American Medical Association Internal Medicine revealed that older persons are highly likely to be excluded from the majority of COVID-19 trials that seek to establish effective treatments, as well as find a preventive vaccine.

28 Sep 2020

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

The vaccine candidate produced a high level of neutralizing antibodies in animal models. Rhesus macaques immunized with the vaccine candidate showed reduced viral loads in the lungs. The research is published on the preprint server bioRxiv.

28 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

New drug offers hope for young boys with Duchenne muscular dystrophy

A new drug offers hope for young boys with the progressive neuromuscular disease Duchenne muscular dystrophy (DMD) by potentially offering an alternative to high-dose glucocorticoids that have significant side effects.

25 Sep 2020

New trial tests combination antibody treatment for preventing COVID-19 illness

A combination antibody treatment for preventing COVID-19 illness in individuals who have had sustained exposure to someone with the virus is being studied by researchers at The University of Texas Health Science Center at Houston.

25 Sep 2020

Women treated with fertility-sparing surgery for ovarian tumors could become pregnant

Women receiving fertility-sparing surgery for treatment of borderline ovarian tumors were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows.

25 Sep 2020

Experimental cancer drug AR-12 inhibits SARS-CoV-2 virus

Nine months into the global pandemic, which has infected more than 32 million people, there is still no approved effective and safe drug or vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

24 Sep 2020

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

A fourth Phase 3 clinical trial evaluating an investigational vaccine for coronavirus disease 2019 (COVID-19) has begun enrolling adult volunteers.

23 Sep 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19.

22 Sep 2020

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

A phase 1 clinical trial of sotorasib (AMG 510) in patients with heavily pretreated advanced solid tumors shows encouraging anti-cancer activity, especially in lung and colorectal cancers, reports a new study led by City of Hope and other renowned comprehensive cancer centers.

22 Sep 2020

Study finds how different strategies may impact clinical trial enrollment

As electronic medical records (EMR) become ubiquitous in health care settings, scientists are increasingly turning to electronic-based recruitment methods to encourage participation in clinical trials.

21 Sep 2020

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and esophageal cancers who currently have poor survival.

21 Sep 2020

PROfound phase III results offer new targeted treatment for metastatic prostate cancer

Results from the PROfound phase III study, funded by AstraZeneca and Merck Sharp & Dohme, open up a much-needed new treatment avenue for the more precise and effective treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed with hormonal therapy.

21 Sep 2020

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits.

21 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Among them is the combination of lopinavir and ritonavir, which have been in use in an attempt to reduce the severity of the disease. However, a new South Korean study published on the preprint server bioRxiv in September 2020 shows that this combination is ineffective against the virus.

20 Sep 2020

Trial shows new first-line treatment option for patients with metastatic kidney cancer

The results of the phase 3 CheckMate 9ER trial have provided a new first-line treatment option for patients with metastatic kidney cancer. The late breaking results are presented at ESMO 2020.

19 Sep 2020

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

As the COVID-19 pandemic continues to cause an immense impact across many parts of the world, the role played by immune responses is becoming more evident every day. A recent funded paper published on the preprint server medRxiv* in September 2020 reports the initiation of a Phase I trial of a drug that increases antibody and cell-mediated immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Sep 2020

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

In a study published on the bioRxiv preprint server, researchers from the University of Pécs, University of Vienna, and CEBINA GmbH, Vienna, show the ability of the antihistamine azelastine to inhibit SARS-CoV-2 infection in human nasal tissue in vitro.

16 Sep 2020

Previous
1
...
67
68
69
70
71
72
73
...
1143
Next

Drug Trial News

Study reveals underrepresentation of older people in COVID-19 trials

Clover Biopharma's new trimeric subunit vaccine candidate prevents COVID-19 in monkeys

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

New drug offers hope for young boys with Duchenne muscular dystrophy

New trial tests combination antibody treatment for preventing COVID-19 illness

Women treated with fertility-sparing surgery for ovarian tumors could become pregnant

Experimental cancer drug AR-12 inhibits SARS-CoV-2 virus

Fourth Phase 3 clinical trial evaluating COVID-19 vaccine begins in the U.S.

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

NIH expands clinical trials to evaluate convalescent plasma as a treatment for COVID-19

Sotorasib phase 1 trial shows encouraging anti-cancer activity in lung, colorectal cancers

Study finds how different strategies may impact clinical trial enrollment

Immunotherapy benefits patients with gastric and esophageal cancers, new data shows

PROfound phase III results offer new targeted treatment for metastatic prostate cancer

KRASG12C inhibitor sotorasib shows durable clinical benefits for solid cancers

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Lopinavir-ritonavir does not suppress SARS-CoV-2 activity in vitro

Trial shows new first-line treatment option for patients with metastatic kidney cancer

Anti-CD73 molecule CPI-006 activates B cell responses to SARS-CoV-2

Azelastine antihistamine inhibits SARS-CoV-2 infection in nasal tissue in vitro

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News